BIOREGENX, INC.
Datakwaliteit: 100%
BRGX
OTC
Technology
IT Services
€ 0,01
€ 0,00
(0,00%)
Marktkapitalisatie: 11,44 M
Prijs
€ 0,01
Marktkapitalisatie
11,44 M
Dagbereik
€ 0,01 — € 0,01
52-Weeksbereik
€ 0,01 — € 0,03
Volume
9.339
Openen € 0,01
50D / 200D Gem.
€ 0,01
9,16% below
50D / 200D Gem.
€ 0,01
12,50% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -48.025,0
Capital efficient — spends only 0,31% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)10420,64%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net Margin-980,96%
Op. Margin-965,35%
Veiligheid
Debt / Equity
N/A
Current Ratio0,07
Interest Coverage-116,53
Waardering
PE (TTM)
-0,60
Onder sectorgemiddelde (-0,16)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Technology sector mediaan (1064 peers)
Sectorvergelijking
vs Technology sector mediaan (1064 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,6 | -0,2 |
| P/B | — | 3,0 |
| ROE % | — | 1,7 |
| Net Margin % | -981,0 | -0,6 |
| Rev Growth 5Y % | — | 7,2 |
| D/E | — | 0,4 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
Geen toekomstige schattingen beschikbaar
No quarterly estimates available
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10420,64% | Revenue Growth (3Y) | 645,03% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,93 M | Net Income (TTM) | -18,93 M |
| ROE | N/A | ROA | -1632,76% |
| Gross Margin | 78,14% | Operating Margin | -965,35% |
| Net Margin | -980,96% | Free Cash Flow (TTM) | -48.025,0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,07 |
| Interest Coverage | -116,53 | Asset Turnover | 1,66 |
| Working Capital | -3,66 M | Tangible Book Value | -4,37 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,60 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 5,93 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -0,42% | ||
| Market Cap | 11,44 M | Enterprise Value | 11,44 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,01 | Revenue / Share | 0,00 |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,31% | FCF Conversion | 0,25% |
| SBC-Adj. FCF | -1,54 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | 2,34 M | 22.243,0 | 42.159,0 |
| Net Income | -23,05 M | -571.171,0 | -78.308,0 |
| EPS (Diluted) | -0,02 | 0,00 | 0,00 |
| Gross Profit | 1,66 M | — | 42.159,0 |
| Operating Income | -22,76 M | -109.663,0 | -78.308,0 |
| EBITDA | — | — | — |
| R&D Expenses | 0,0 | — | — |
| SG&A Expenses | 5,85 M | — | — |
| D&A | 2,22 M | — | — |
| Interest Expense | 6.638,0 | 8.276,0 | — |
| Income Tax | — | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Total Assets | 508.535,0 | 31.640,0 | 59.149,0 |
| Total Liabilities | 3,89 M | 253.612,0 | 260.691,0 |
| Shareholders' Equity | -3,38 M | -221.972,0 | -201.542,0 |
| Total Debt | 1,14 M | 200.000,0 | 200.000,0 |
| Cash & Equivalents | 58.404,0 | — | — |
| Current Assets | 307.796,0 | 0,0 | 676,0 |
| Current Liabilities | 3,63 M | 253.612,0 | 64.880,0 |
{"event":"ticker_viewed","properties":{"ticker":"BRGX","listing_kind":"stock","pathname":"/stocks/brgx","exchange":"OTC","country":"US"}}